The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Abstract East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily pract...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis and haemostasis Vol. 121; no. 4; pp. 422 - 432
Main Authors: Kim, Hyun Kuk, Tantry, Udaya S., Smith, Sidney C., Jeong, Myung Ho, Park, Seung-Jung, Kim, Moo Hyun, Lim, Do-Sun, Shin, Eun-Seok, Park, Duk-Woo, Huo, Yong, Chen, Shao-Liang, Bo, Zheng, Goto, Shinya, Kimura, Takeshi, Yasuda, Satoshi, Chen, Wen-Jone, Chan, Mark, Aradi, Daniel, Geisler, Tobias, Gorog, Diana A., Sibbing, Dirk, Lip, Gregory Y. H., Angiolillo, Dominick J., Gurbel, Paul A., Jeong, Young-Hoon
Format: Journal Article
Language:English
Published: Rüdigerstraße 14, 70469 Stuttgart, Germany Georg Thieme Verlag KG 01.04.2021
Subjects:
Review Article
direct oral anticoagulants
bleeding risk
antiplatelet therapy
race
ischemic risk
ISSN:0340-6245, 2567-689X, 2567-689X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk–benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
ObjectType-Review-4
content type line 23
ISSN:0340-6245
2567-689X
2567-689X
DOI:10.1055/s-0040-1718729